{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T05:07:11Z","timestamp":1745644031345},"reference-count":17,"publisher":"Japanese Society of Internal Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,4,15]]},"DOI":"10.2169\/internalmedicine.1492-22","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T22:54:10Z","timestamp":1695941650000},"page":"1105-1112","source":"Crossref","is-referenced-by-count":2,"title":["Intrahepatic Cholangiocarcinoma with High Microsatellite Instability and Tumor Mutation Burden That Responded Significantly to Pembrolizumab but Perforated within a Short Period"],"prefix":"10.2169","volume":"63","author":[{"given":"Shiori","family":"Yamazaki","sequence":"first","affiliation":[{"name":"Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kubota","sequence":"additional","affiliation":[{"name":"Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Notake","sequence":"additional","affiliation":[{"name":"Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Umemura","sequence":"additional","affiliation":[{"name":"Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kamachi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takamune","family":"Goto","sequence":"additional","affiliation":[{"name":"Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Tomida","sequence":"additional","affiliation":[{"name":"Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naho","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Shinshu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Midori","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Shinshu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kanno","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shinshu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Soejima","sequence":"additional","affiliation":[{"name":"Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362: 1273-1281, 2010.","DOI":"10.1056\/NEJMoa0908721"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Milbury CA, Creeden J, Yip WK, et al. Clinical and analytical validation of FoundationOne<sup>\u00ae<\/sup>CDx, a comprehensive genomic profiling assay for solid tumors. PLoS One 17: e0264138, 2022.","DOI":"10.1371\/journal.pone.0264138"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Sanchez-Vega F, Mina M, Armenia J, et al. Oncogenic signaling pathways in the cancer genome atlas. Cell 173: 321-337, 2018.","DOI":"10.1016\/j.cell.2018.03.035"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372: 2018-2028, 2015.","DOI":"10.1056\/NEJMoa1501824"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 378: 1789-1801, 2018.","DOI":"10.1056\/NEJMoa1802357"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Keating M, Giscombe L, Tannous T, Hartshorn K. Prolonged treatment response to pembrolizumab in a patient with pretreated metastatic colon cancer and Lynch syndrome. Case Rep Oncol Med 2019: 3847672, 2019.","DOI":"10.1155\/2019\/3847672"},{"key":"7","unstructured":"7. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 38: 1-10, 2020."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21: 1353-1365, 2020.","DOI":"10.1016\/S1470-2045(20)30445-9"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Li H, Zhang ZY, Zhou ZQ, Guan J, Tong DN, Zhou GW. Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial. Oncotarget 7: 26888-26897, 2016.","DOI":"10.18632\/oncotarget.8590"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 127: 1335-1339, 1992.","DOI":"10.1001\/archsurg.1992.01420110083017"},{"key":"11","unstructured":"11. Japanese Society of Hepato-Biliary-Pancreatic Surgery. General rules for clinical and pathological studies on cancer of the biliary tract. 7th edition. Japanese Society of Hepato-Biliary-Pancreatic Surgery, Tokyo, 2021: 77-78."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med 7: 746-756, 2018.","DOI":"10.1002\/cam4.1372"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Oh DY, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 1: 2022.","DOI":"10.1056\/EVIDoa2200015"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Oliver K, Damien K, Adnan N, et al. Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers. JAMA Oncol 6: 1405-1409, 2020.","DOI":"10.1001\/jamaoncol.2020.2814"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Darnell EP, Mooradian MJ, Baruch EN, Yilmaz M, Reynolds KL. Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls. Curr Oncol Rep 22: 39, 2020.","DOI":"10.1007\/s11912-020-0897-9"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Alshari OM, Dawaymeh TA, Tashtush NA, Aleshawi AJ, Al Manasra ARA, Obeidat KA. Completely resolved advanced biliary tract cancer after treatment by pembrolizumab: a report of two cases. Onco Targets Ther 12: 5293-5298, 2019.","DOI":"10.2147\/OTT.S197559"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Abudalou M, Vega EA, Kondratiev S, Conrad C, Kozyreva O. Complete pathological response to neoadjuvant chemoimmunotherapy in a patient with metastatic intrahepatic cholangiocarcinoma with high tumor mutational burden. Cureus 13: e20187, 2021.","DOI":"10.7759\/cureus.20187"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/8\/63_1492-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T03:30:43Z","timestamp":1713583843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/8\/63_1492-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1492-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]},"article-number":"1492-22"}}